A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages

Nature Cell Biology

Volumn 16, Issue 11, 2014, Pages 1105-1117

  Lu, Haihui ^a,b   Clauser, Karl R ^b   Tam, Wai Leong ^a,b,c   Fröse, Julia ^a,d,e   Ye, Xin ^a   Eaton, Elinor Ng ^a   Reinhardt, Ferenc ^a   Donnenberg, Vera S ^f,g   Bhargava, Rohit ^h   Carr, Steven A ^b   Weinberg, Robert A ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE KINASE; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; JUXTACRINE SIGNALLING; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; MICE; MONOCYTES; NEOPLASTIC STEM CELLS; NF-KAPPA B; SIGNAL TRANSDUCTION; STEM CELL NICHE;

EID: 84908485098     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3041     Document Type: Article

References (67)

1. Huber, M. A., Kraut, N. & Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17, 548-558 (2005).
2. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
3. Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028 (2012).
4. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
5. Morel, A. P. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3, e2888 (2008).
6. Buck, E. et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 6, 532-541 (2007).
7. Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106, 13820-13825 (2009).
8. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).
9. Li, H. J., Reinhardt, F., Herschman, H. R. & Weinberg, R. A. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2, 840-855 (2012).
10. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2011).
11. Merlos-Suarez, A. et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8, 511-524 (2011).
12. Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445-455 (2013).
13. Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286-291 (2013).
14. Gyorki, D. E., Asselin-Labat, M. L., Rooijen, N. v., Lindeman, G. J. & Visvader, J. E. Resident macrophages influence stem cell activity in the mammary gland. Breast Cancer Res. 11, R62 (2009).
15. Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65 (2001).
16. Ong, S. E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteom. 1, 376-386 (2002).
17. Udeshi, N. D. et al. Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol. Cell. Proteomics 11, 148-159 (2012).
18. Barker, T. H. & Hagood, J. S. Getting a grip on Thy-1 signaling. Biochim. Biophys. Acta. 1793, 921-923 (2009).
19. Wetzel, A. et al. Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J. Immunol. 172, 3850-3859 (2004).
20. Lim, E. et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 12, R21 (2010).
21. Shipitsin, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (2007).
22. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003).
23. Tsuchiya, S. et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26, 171-176 (1980).
24. Donnenberg, V. S. et al. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin. Cytom. 78, 287-301 (2010).
25. Donnenberg, A. D., Zimmerlin, L., Landreneau, R. J., Luketich, J. D. & Donnenberg, V. S. KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients. PLoS ONE 7, 1-11 (2012).
26. Medrek, C., Ponten, F., Jirstrom, K. & Leandersson, K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306 (2012).
27. Tsutsui, S. et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 14, 425-431 (2005).
28. Ch'ng, E. S., Tuan Sharif, S. E. & Jaafar, H. In human invasive breast ductal carcinoma, tumor stromal macrophages and tumor nest macrophages have distinct relationships with clinicopathological parameters and tumor angiogenesis. Virchows Arch. 462, 257-267 (2013).
29. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51 (2010).
30. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-737 (2011).
31. Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001).
32. Ohri, C. M., Shikotra, A., Green, R. H., Waller, D. A. & Bradding, P. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS ONE 6, e21874 (2011).
33. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
34. Hartman, Z. C. et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. (2013).
35. Korkaya, H., Liu, S. & Wicha, M. S. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin. Cancer Res. 17, 6125-6129 (2011).
36. Wyckoff, J. et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64, 7022-7029 (2004).
37. Tam, W. L. et al. Protein Kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347-364 (2013).
38. Thomson, S., Petti, F., Sujka-Kwok, I., Epstein, D. & Haley, J. D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 25, 843-854 (2008).
39. Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L. & Comoglio, P. M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132-3141 (2011).
40. Pasquale, E. B. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165-180 (2010).
41. Lamberto, I. et al. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem. J. 445, 47-56 (2012).
42. Zhou, L. et al. EphA4 signaling regulates phospholipase Cgamma1 activation, cofilin membrane association, and dendritic spine morphology. J. Neurosci. 27, 5127-5138 (2007).
43. Griner, E. M. & Kazanietz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 7, 281-294 (2007).
44. Kalo, M. S. & Pasquale, E. B. Signal transfer by eph receptors. Cell Tissue Res. 298, 1-9 (1999).
45. Lu, Z. G., Liu, H., Yamaguchi, T., Miki, Y. & Yoshida, K. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha. Cancer Res. 69, 5927-5935 (2009).
46. Hoffmann, E., Dittrich-Breiholz, O., Holtmann, H. & Kracht, M. Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 72, 847-855 (2002).
47. Sasaki, C. Y., Ghosh, P. & Longo, D. L. Recruitment of RelB to the Csf2 promoter enhances RelA-mediated transcription of granulocyte-macrophage colony-stimulating factor. J. Biol. Chem. 286, 1093-1102 (2011).
48. Yoon, S. et al. NF-kappaB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene. 31, 3467-3481 (2012).
49. Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404, 892-897 (2000).
50. Li, S. et al. TWIST1 associates with NF-kappaB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol. 10, 73 (2012).
51. Gisina, A. M. et al. Detection of minor subpopulations of colorectal adenocarcinoma cells expressing cancer stem cell markers. Bull. Exp. Biol. Med. 151, 234-238 (2011).
52. He, J. et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol. Cell. Proteomics 11, M111 010744 (2012).
53. Jiang, J. et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene. 31, 671-682 (2012).
54. Yang, Z. F. et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13, 153-166 (2008).
55. Oki, M. et al. Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J. Gastroenterol. 14, 5650-5656 (2008).
56. Oshima, T. et al. Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer. Int. J. Oncol. 33, 573-577 (2008).
57. Binda, E. et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22, 765-780 (2012).
58. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res. Treat. 123, 725-731 (2010).
59. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
60. Yu, M. et al. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 23, 1737-1742 (2009).
61. Shibue, T. & Weinberg, R. A. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl Acad. Sci. USA 106, 10290-10295 (2009).
62. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G. & Verma, I. p53 stabilization is decreased upon NFkappaB activation: A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1, 493-503 (2002).
63. Stewart, S. A. et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493-501 (2003).
64. Han, J. et al. Tbx3 improves the germ-line competency of induced pluripotent stem cells. Nature 463, 1096-1100 (2010).
65. Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009).
66. Hammond, S. L., Ham, R. G. & Stampfer, M. R. Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc. Natl Acad. Sci. USA 81, 5435-5439 (1984).
67. Naba, A. et al. The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteomics 11, M111 014647 (2012).